Logo image of GLPG.AS

GALAPAGOS NV (GLPG.AS) Stock Fundamental Analysis

AMS:GLPG - Euronext Amsterdam - BE0003818359 - Common Stock - Currency: EUR

23.72  +0.1 (+0.42%)

Fundamental Rating

3

GLPG gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 69 industry peers in the Biotechnology industry. Both the profitability and the financial health of GLPG get a neutral evaluation. Nothing too spectacular is happening here. GLPG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year GLPG was profitable.
GLPG had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: GLPG reported negative net income in multiple years.
In the past 5 years GLPG always reported negative operating cash flow.
GLPG.AS Yearly Net Income VS EBIT VS OCF VS FCFGLPG.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

1.2 Ratios

The Return On Assets of GLPG (2.97%) is better than 81.16% of its industry peers.
With an excellent Return On Equity value of 4.24%, GLPG belongs to the best of the industry, outperforming 81.16% of the companies in the same industry.
Industry RankSector Rank
ROA 2.97%
ROE 4.24%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GLPG.AS Yearly ROA, ROE, ROICGLPG.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30

1.3 Margins

GLPG has a Profit Margin of 23.04%. This is amongst the best in the industry. GLPG outperforms 92.75% of its industry peers.
In the last couple of years the Profit Margin of GLPG has grown nicely.
With an excellent Gross Margin value of 89.88%, GLPG belongs to the best of the industry, outperforming 88.41% of the companies in the same industry.
GLPG's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 23.04%
GM 89.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y6.72%
GM growth 3Y-3.72%
GM growth 5YN/A
GLPG.AS Yearly Profit, Operating, Gross MarginsGLPG.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100

More info and screens

5

2. Health

2.1 Basic Checks

GLPG does not have a ROIC to compare to the WACC, probably because it is not profitable.
GLPG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GLPG.AS Yearly Shares OutstandingGLPG.AS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
GLPG.AS Yearly Total Debt VS Total AssetsGLPG.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B

2.2 Solvency

GLPG has an Altman-Z score of 1.46. This is a bad value and indicates that GLPG is not financially healthy and even has some risk of bankruptcy.
GLPG has a Altman-Z score of 1.46. This is in the better half of the industry: GLPG outperforms 65.22% of its industry peers.
GLPG has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
GLPG has a better Debt to Equity ratio (0.00) than 92.75% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.46
ROIC/WACCN/A
WACC7.66%
GLPG.AS Yearly LT Debt VS Equity VS FCFGLPG.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

2.3 Liquidity

A Current Ratio of 9.97 indicates that GLPG has no problem at all paying its short term obligations.
The Current ratio of GLPG (9.97) is better than 97.10% of its industry peers.
A Quick Ratio of 9.81 indicates that GLPG has no problem at all paying its short term obligations.
The Quick ratio of GLPG (9.81) is better than 97.10% of its industry peers.
Industry RankSector Rank
Current Ratio 9.97
Quick Ratio 9.81
GLPG.AS Yearly Current Assets VS Current LiabilitesGLPG.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B 4B 5B

More info and screens

1

3. Growth

3.1 Past

GLPG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -65.54%.
The earnings per share for GLPG have been decreasing by -12.47% on average. This is quite bad
Looking at the last year, GLPG shows a very negative growth in Revenue. The Revenue has decreased by -31.28% in the last year.
GLPG shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -18.61% yearly.
EPS 1Y (TTM)-65.54%
EPS 3YN/A
EPS 5Y-12.47%
EPS Q2Q%-84.1%
Revenue 1Y (TTM)-31.28%
Revenue growth 3Y-16.25%
Revenue growth 5Y-18.61%
Sales Q2Q%-77.44%

3.2 Future

GLPG is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -40.64% yearly.
The Revenue is expected to decrease by -0.42% on average over the next years.
EPS Next Y-149.06%
EPS Next 2Y-82.47%
EPS Next 3Y-62.38%
EPS Next 5Y-40.64%
Revenue Next Year-6.96%
Revenue Next 2Y-3.43%
Revenue Next 3Y-5.85%
Revenue Next 5Y-0.42%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
GLPG.AS Yearly Revenue VS EstimatesGLPG.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
GLPG.AS Yearly EPS VS EstimatesGLPG.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 21.18, GLPG is valued on the expensive side.
Based on the Price/Earnings ratio, GLPG is valued cheaply inside the industry as 88.41% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 28.89. GLPG is valued slightly cheaper when compared to this.
The Forward Price/Earnings Ratio is negative for GLPG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 21.18
Fwd PE N/A
GLPG.AS Price Earnings VS Forward Price EarningsGLPG.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLPG.AS Per share dataGLPG.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

A cheap valuation may be justified as GLPG's earnings are expected to decrease with -62.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-82.47%
EPS Next 3Y-62.38%

More info and screens

0

5. Dividend

5.1 Amount

GLPG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GALAPAGOS NV

AMS:GLPG (3/27/2025, 9:36:43 AM)

23.72

+0.1 (+0.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12 2025-02-12/amc
Earnings (Next)04-23 2025-04-23
Inst Owners48.62%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap1.56B
Analysts50
Price Target30.84 (30.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)50.56%
Min EPS beat(2)-52.97%
Max EPS beat(2)154.1%
EPS beat(4)3
Avg EPS beat(4)329.61%
Min EPS beat(4)-52.97%
Max EPS beat(4)1052.58%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-13.66%
Min Revenue beat(2)-15.5%
Max Revenue beat(2)-11.82%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.63%
PT rev (3m)-13.78%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-2.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.37%
Revenue NY rev (3m)-1.3%
Valuation
Industry RankSector Rank
PE 21.18
Fwd PE N/A
P/S 2.93
P/FCF N/A
P/OCF N/A
P/B 0.54
P/tB 0.59
EV/EBITDA N/A
EPS(TTM)1.12
EY4.72%
EPS(NY)-0.55
Fwd EYN/A
FCF(TTM)-6.1
FCFYN/A
OCF(TTM)-4.86
OCFYN/A
SpS8.09
BVpS43.96
TBVpS40.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.97%
ROE 4.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 23.04%
GM 89.88%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y6.72%
GM growth 3Y-3.72%
GM growth 5YN/A
F-Score2
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 15.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.97
Quick Ratio 9.81
Altman-Z 1.46
F-Score2
WACC7.66%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)15.33%
Cap/Sales(5y)14.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-65.54%
EPS 3YN/A
EPS 5Y-12.47%
EPS Q2Q%-84.1%
EPS Next Y-149.06%
EPS Next 2Y-82.47%
EPS Next 3Y-62.38%
EPS Next 5Y-40.64%
Revenue 1Y (TTM)-31.28%
Revenue growth 3Y-16.25%
Revenue growth 5Y-18.61%
Sales Q2Q%-77.44%
Revenue Next Year-6.96%
Revenue Next 2Y-3.43%
Revenue Next 3Y-5.85%
Revenue Next 5Y-0.42%
EBIT growth 1Y-269.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.68%
EBIT Next 3Y-17.01%
EBIT Next 5Y-15.13%
FCF growth 1Y5.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.17%
OCF growth 3YN/A
OCF growth 5YN/A